ISSN: 2472-4971
Sudha Jimson*, Samson Jimson, Lokesh Bhanumurthy, Julius Amalada, Kesavaram Padmavathy
WHO Classification of Head and Neck Tumours (2017) defines Ameloblastoma as benign intraosseous progressively growing epithelial odontogenic neoplasm characterized by expansion and a tendency for local recurrence if not adequately removed. It reports annual incidence of about 0.5 cases per million populations but it is considered to be the most common odontogenic tumour next to odontoma with a varied global prevalence. Although, there are several researches, reports and reviews on ameloblastoma; our review discusses the recent updates with emphasize on molecular pathobiology of ameloblastoma and also revolves around the controversies on radical vs. conservative management with updates on chemotherapeutic management. This scenario suggested us to clarify the prospects in management of ameloblastoma with the available scientific literature. Our narrative review aims to address recent updates on clinical, surgical management, adjuvant therapies with relevance to clinico-pathological and radiological features and also molecular aspects in relation to management of ameloblastoma.